Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Storek

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Bone Marrow Transplantation|November 9, 2010
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATGS El Kourashy, T Williamson, M A Chaudhry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 1996
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recoveryK M Sullivan, J Storek, K J Kopecky, et al.
Bone Marrow Transplantation|August 28, 2003
Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantationChien-Shing Chen, M Boeckh, K Seidel, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|May 3, 2012
No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantationM Tomblyn, M Chen, M Kukreja, et al.
Advanced Therapeutics|October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating NeuropathiesJohn W Rumsey, Case Lorance, Max Jackson, et al.
Mabs|March 2, 2010
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2Roni Mamluk, Irvith M Carvajal, Brent A Morse, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 21, 2024
C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complementFei Liu, Sarah T Ryan, Kelly C Fahnoe, et al.
Bone Marrow Transplantation|January 5, 2016
The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysisK M Williams, K W Ahn, M Chen, et al.
Bone Marrow Transplantation|December 13, 2016
GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomesY-B Chen, T Wang, M T Hemmer, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Bone Marrow Transplantation|November 9, 2010
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATGS El Kourashy, T Williamson, M A Chaudhry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 1996
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recoveryK M Sullivan, J Storek, K J Kopecky, et al.
Bone Marrow Transplantation|August 28, 2003
Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantationChien-Shing Chen, M Boeckh, K Seidel, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|May 3, 2012
No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantationM Tomblyn, M Chen, M Kukreja, et al.
Advanced Therapeutics|October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating NeuropathiesJohn W Rumsey, Case Lorance, Max Jackson, et al.
Mabs|March 2, 2010
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2Roni Mamluk, Irvith M Carvajal, Brent A Morse, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 21, 2024
C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complementFei Liu, Sarah T Ryan, Kelly C Fahnoe, et al.
Bone Marrow Transplantation|January 5, 2016
The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysisK M Williams, K W Ahn, M Chen, et al.
Bone Marrow Transplantation|December 13, 2016
GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomesY-B Chen, T Wang, M T Hemmer, et al.
Pageof 8